Prostaglandin E1 infusion compared with prostacyclin infusion in patients with refractory heart failure: effects on hemodynamics and neurohumoral variables

J Heart Lung Transplant. 1997 Aug;16(8):878-81.

Abstract

Prostaglandin E1 or prostacyclin were randomly infused in 18 patients with severe chronic heart failure who did not respond to oral treatment. Maximally tolerated dosages of both agents increased cardiac index; however, only prostacyclin decreased mean arterial pressure and increased plasma norepinephrine significantly. Twelve hours after 50% peak dose reduction, atrial natriuretic peptide levels, right atrial pressure, mean pulmonary artery pressure, and mean arterial pressure continued to decrease with prostaglandin E1, whereas the increase in cardiac index was sustained; in contrast, at 50% prostacyclin dose reduction, cardiac index decreased toward baseline, suggesting that, with reduced dosages for chronic infusions, desired hemodynamic changes seem to be sustained with prostaglandin E1 only.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Alprostadil / administration & dosage*
  • Alprostadil / adverse effects
  • Antihypertensive Agents / administration & dosage*
  • Antihypertensive Agents / adverse effects
  • Atrial Natriuretic Factor / blood
  • Blood Pressure / drug effects
  • Blood Pressure / physiology
  • Cardiac Output / drug effects
  • Cardiac Output / physiology
  • Dose-Response Relationship, Drug
  • Endothelin-1
  • Endothelins / blood
  • Epoprostenol / administration & dosage*
  • Epoprostenol / adverse effects
  • Female
  • Heart Failure / drug therapy*
  • Heart Failure / physiopathology
  • Hemodynamics / drug effects*
  • Hemodynamics / physiology
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Neurotransmitter Agents / blood*
  • Protein Precursors / blood
  • Pulmonary Wedge Pressure / drug effects
  • Pulmonary Wedge Pressure / physiology
  • Vasodilator Agents / administration & dosage*
  • Vasodilator Agents / adverse effects

Substances

  • Antihypertensive Agents
  • Endothelin-1
  • Endothelins
  • Neurotransmitter Agents
  • Protein Precursors
  • Vasodilator Agents
  • Atrial Natriuretic Factor
  • Epoprostenol
  • Alprostadil